These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16918361)

  • 1. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20).
    Manfredi R; Sabbatani S
    Curr Med Chem; 2006; 13(20):2369-84. PubMed ID: 16918361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
    Fung HB; Guo Y
    Clin Ther; 2004 Mar; 26(3):352-78. PubMed ID: 15110129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enfuvirtide: first fusion inhibitor for treatment of HIV infection.
    Jamjian MC; McNicholl IR
    Am J Health Syst Pharm; 2004 Jun; 61(12):1242-7. PubMed ID: 15259753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enfuvirtide.
    Lalezari JP; Luber AD
    Drugs Today (Barc); 2004 Mar; 40(3):259-69. PubMed ID: 15148534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfuvirtide: a review of its use in the management of HIV infection.
    Oldfield V; Keating GM; Plosker G
    Drugs; 2005; 65(8):1139-60. PubMed ID: 15907147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enfuvirtide: the first HIV fusion inhibitor.
    Lazzarin A
    Expert Opin Pharmacother; 2005 Mar; 6(3):453-64. PubMed ID: 15794736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1].
    Raffi F
    Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enfuvirtide (Fuzeon): the first fusion inhibitor.
    Williams IG
    Int J Clin Pract; 2003 Dec; 57(10):890-7. PubMed ID: 14712892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Enfuvirtide: first drug of a new family of antiretroviral agents].
    Espona M; Ferrández O; Grau S; Carmona A
    Farm Hosp; 2005; 29(6):375-83. PubMed ID: 16433570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
    Cooper DA; Lange JM
    Lancet Infect Dis; 2004 Jul; 4(7):426-36. PubMed ID: 15219553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfuvirtide (T-20): potentials and challenges.
    Foy K; Juethner SN
    J Assoc Nurses AIDS Care; 2004; 15(6):65-71. PubMed ID: 15538017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Enfuvirtide, mechanism of action and pharmacological properties].
    Kapić E; Becić F; Zvizdić S
    Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
    Pham PA
    Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
    [No Abstract]   [Full Text] [Related]  

  • 16. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
    Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
    J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV fusion and its inhibition in antiretroviral therapy.
    Greenberg M; Cammack N; Salgo M; Smiley L
    Rev Med Virol; 2004; 14(5):321-37. PubMed ID: 15334539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfuvirtide: from basic investigations to current clinical use.
    Joly V; Jidar K; Tatay M; Yeni P
    Expert Opin Pharmacother; 2010 Nov; 11(16):2701-13. PubMed ID: 20977403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
    J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.